RESEARCH MONOGRAPH · KDC-MN-233

Quetiapine

May 9, 2026 Kodiac biolabs Research Revised May 11, 2026 3 min read

Our opinion on this compound

77/100

Multireceptor sedating atypical thats more interesting as a tool compound than its low-dose reputation suggests

Quetiapine is one of the more interesting atypical antipsychotics because its pharmacology shifts dramatically with exposure. At low concentrations you get mostly H1 antagonism and alpha-1 antagonism, which is why low-dose quetiapine is everywhere in psychiatry as an off-label hypnotic and anxiolytic. At higher exposures you start hitting 5-HT2A inverse agonism meaningfully, and only at the higher end does D2 antagonism become substantial. Thats unusual. Most antipsychotics dose into D2 territory first.

The active metabolite norquetiapine adds another layer. Norquetiapine is a NET reuptake inhibitor with potency in the low nanomolar range, plus 5-HT1A partial agonism. So chronic quetiapine exposure produces a parent compound thats sedating and weakly D2-active alongside a metabolite that looks more like an SNRI with serotonergic tilt. The antidepressant efficacy in bipolar depression that quetiapine carved out a niche for is almost certainly mediated through the norquetiapine pharmacology rather than the parent.

For research thats genuinely useful. Single clinical-grade molecule that gives you exposure-dependent receptor pharmacology plus an active metabolite with a separate mechanism. If you want to study what happens when you stack H1 and alpha-1 antagonism with NET inhibition and 5-HT1A partial agonism, quetiapine plus norquetiapine is one of very few clinical compounds that delivers that combination natively.

What we dont like is how loosely the compound gets handled clinically. Low-dose quetiapine prescribed as a sleep aid has become a public-health-scale prescribing pattern with thin evidence and real metabolic-syndrome risk that the prescribers usually arent monitoring. None of that touches in vitro research but it shapes how the clinical literature reads.

Sourcing is solid. Fumarate salt is standard, reference material widely available, HPLC validation straightforward. Both quetiapine and norquetiapine reference standards are accessible.

The CYP3A4 metabolism is worth knowing about because it makes drug-drug interaction studies clean if youre doing that kind of pharmacokinetic work.

Honestly, more pharmacologically interesting as a research tool than its clinical positioning suggests. Worth keeping in mind.

Evidence: 85
Mechanism: 78
Reliability: 82
Safety: 70
Sourcing: 85
Value: 78
Signal: 70
Staying power: 72

Plain-language summary Intrigue 65 / 100

Quetiapine (Seroquel) is a workhorse atypical antipsychotic from AstraZeneca, approved in 1997, that has become equally famous as an off-label sleep aid because its potent histamine-receptor blockade makes the low-dose form (25 to 100 mg) profoundly sedating. At full antipsychotic doses (300 to 800 mg) it is used for schizophrenia and acute mania. At intermediate doses (150 to 300 mg) it is FDA-approved for bipolar depression and as add-on for major depression. The active leftover after liver metabolism, norquetiapine, blocks the norepinephrine pump and contributes to the antidepressant effect. Metabolic side effects (weight gain, lipid and glucose disturbance) are real and dose-related, which has prompted concern about its widespread use as a sleep drug. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Atypical antipsychotic

A dibenzothiazepine atypical antipsychotic with broad receptor binding; the active metabolite norquetiapine is a NET inhibitor contributing to antidepressant efficacy.

Abstract

Quetiapine (2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-piperazin-1-yl)ethoxy]ethanol; CAS 111974-69-7; molecular formula C21H25N3O2S; molecular weight 383.51) is a dibenzothiazepine atypical antipsychotic developed at AstraZeneca and approved by the FDA in 1997 under the trade name Seroquel. The receptor profile is broad: D2 (Ki approximately 770 nM, the weakest of the antipsychotic class), 5-HT2A (Ki approximately 295 nM), H1 (Ki approximately 11 nM), alpha-1 (Ki approximately 22 nM), 5-HT1A partial agonism. The active metabolite norquetiapine (formed via CYP3A4) is a potent NET inhibitor (Ki approximately 35 nM) and a 5-HT2C antagonist, contributing to antidepressant efficacy and supporting the FDA-approved adjunctive use in major depressive disorder. Plasma half-life is 6 to 7 hours; metabolism is via CYP3A4. Approved for schizophrenia, bipolar I disorder (mania, depression, maintenance), and adjunctive in MDD. Off-label use as a hypnotic at 25 to 100 mg is widespread despite a poor efficacy-to-side-effect ratio for that indication. Used as a reference broad-spectrum atypical antipsychotic in mechanism studies.

Mechanism of action

Weak D2 antagonism, broad receptor profile (5-HT2A, H1, alpha-1, 5-HT1A partial agonism). Active metabolite norquetiapine is a NET inhibitor and 5-HT2C antagonist.

Reported research dose ranges

Clinical 25 to 800 mg per oral administration daily (low for off-label hypnotic, high for psychosis/mania). Rodent studies 5 to 50 mg/kg/day.

References

Goldstein JM. Quetiapine fumarate: a new atypical antipsychotic. Drugs Today 1999.
Jensen NH, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008.
Maneeton N, et al. Quetiapine monotherapy for major depressive disorder: a systematic review and meta-analysis. CNS Drugs 2014.

Read the full monograph

The full reference document is available below as a PDF embed and download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-233 Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Quetiapine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs